Kimberly-Clark Slashes FY21 Outlook - Quick Facts

While reporting financial results for the second quarter on Friday, consumer products firm Kimberly-Clark Corp. (KMB) slashed its adjusted earnings and sales growth guidance for the full-year 2021.

For fiscal 2021, the company now projects adjusted earnings in a range of $6.65 to $6.90 per share on net sales growth of 1 to 4 percent, with organic sales growth of flat to 2 percent.

Previously, the company expected adjusted earnings in the range of $7.30 to $7.55 per share on net sales growth of 3 to 5 percent, with organic sales growth of flat to 1 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $7.35 per share on sales growth of 2.9 percent to $19.69 billion for the year. Analysts' estimates usually exclude special items.

Kimberly-Clark said it expects the global restructuring program initiated in January 2018 to be completed in 2021. As part of the program, Kimberly-Clark expects to exit or divest some low-margin businesses that generate about 1 percent of company net sales.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT